We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
Read MoreHide Full Article
Biogen Inc (BIIB - Free Report) announced that it has signed a commercialization and license agreement with Sweden-based biological drug-maker, Xbrane Biopharma AB, to gain exclusive regulatory, manufacturing, and commercial rights to Xbrane’s pre-clinical biosimilar candidate, Xcimzane.
Per the agreement, Biogen will pay $8 million upfront and up to $80 million in potential milestone payments to Xbrane for exclusive global regulatory, manufacturing, and commercial rights to Xcimzane. Biogen will also be the marketing authorization holder following a potential approval to the candidate. Biogen will also pay royalties on potential sales of Xcimzane going forward. While Xbrane will be responsible for the pre-clinical development of Xcimzane, Biogen will undertake remaining development activities as well as associated costs through to an approval for the candidate.
We note that the UCB’s Cimzia is a tumor necrosis factor (“TNF”) blocker approved for several inflammatory indications including Crohn’s disease and psoriatic arthritis. UCB garnered revenues of almost $1 billion in the first half of 2021 from Cimzia sales. The blockbuster inflammatory drug from UCB’s portfolio is set to lose patent protection in the United States in 2024. UCB’s drug lost patent protection in Europe last year.
The agreement with Xbrane should help Biogen boost its biosimilar portfolio going forward with the addition of Xcimzane. Currently, Biogen markets three biosimilar drugs — Flixabi (a biosimilar referencing Remicade), Benepali (a biosimilar referencing Enbrel) and Imraldi (a biosimilar referencing Humira) — primarily in Europe.
The company gained FDA approval for Byooviz, referencing Roche’s (RHHBY - Free Report) Lucentis, last year. Biogen may start its commercialization in the second of 2022, per an agreement with Roche. Roche’s branded drug Lucentis generated more than $2 billion in sales in 2021.
Apart from these four biosimilars, Biogen has several biosimilar candidates in its pipeline including SB15, which references Regeneron’s (REGN - Free Report) eye drug, Eylea.
Regeneron’s Eylea-referencing candidate is currently in late-stage development. We note that Regeneron generated $5.8 billion from the sale of Eylea in 2021.
In the past year, Biogen’s shares have declined 17.7% compared with the industry’s decrease of 40.7% in the same time frame.
Image Source: Zacks Investment Research
Biogen’s biosimilar portfolio recorded sales of $831 million in 2021. None of the biosimilar drugs from the company’s portfolio are currently marketed in the United States. Please note that Biogen had a joint venture with Samsung Bioepis for the development and commercialization of its biosimilar drugs. However, Biogen announced an agreement last month to sell its 49.9% equity stake in the joint venture for up to $2.3 billion. Per the terms of the agreement, the companies will continue with their exclusive agreements for the commercialization of Flixabi, Benepali and Imraldi. Biogen will also keep commercial rights for Byooviz and SB15.
Image: Shutterstock
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
Biogen Inc (BIIB - Free Report) announced that it has signed a commercialization and license agreement with Sweden-based biological drug-maker, Xbrane Biopharma AB, to gain exclusive regulatory, manufacturing, and commercial rights to Xbrane’s pre-clinical biosimilar candidate, Xcimzane.
The monoclonal antibody candidate, Xcimzane references UCB’s rheumatoid arthritis drug, Cimzia.
Per the agreement, Biogen will pay $8 million upfront and up to $80 million in potential milestone payments to Xbrane for exclusive global regulatory, manufacturing, and commercial rights to Xcimzane. Biogen will also be the marketing authorization holder following a potential approval to the candidate. Biogen will also pay royalties on potential sales of Xcimzane going forward. While Xbrane will be responsible for the pre-clinical development of Xcimzane, Biogen will undertake remaining development activities as well as associated costs through to an approval for the candidate.
We note that the UCB’s Cimzia is a tumor necrosis factor (“TNF”) blocker approved for several inflammatory indications including Crohn’s disease and psoriatic arthritis. UCB garnered revenues of almost $1 billion in the first half of 2021 from Cimzia sales. The blockbuster inflammatory drug from UCB’s portfolio is set to lose patent protection in the United States in 2024. UCB’s drug lost patent protection in Europe last year.
The agreement with Xbrane should help Biogen boost its biosimilar portfolio going forward with the addition of Xcimzane. Currently, Biogen markets three biosimilar drugs — Flixabi (a biosimilar referencing Remicade), Benepali (a biosimilar referencing Enbrel) and Imraldi (a biosimilar referencing Humira) — primarily in Europe.
The company gained FDA approval for Byooviz, referencing Roche’s (RHHBY - Free Report) Lucentis, last year. Biogen may start its commercialization in the second of 2022, per an agreement with Roche. Roche’s branded drug Lucentis generated more than $2 billion in sales in 2021.
Apart from these four biosimilars, Biogen has several biosimilar candidates in its pipeline including SB15, which references Regeneron’s (REGN - Free Report) eye drug, Eylea.
Regeneron’s Eylea-referencing candidate is currently in late-stage development. We note that Regeneron generated $5.8 billion from the sale of Eylea in 2021.
In the past year, Biogen’s shares have declined 17.7% compared with the industry’s decrease of 40.7% in the same time frame.
Biogen’s biosimilar portfolio recorded sales of $831 million in 2021. None of the biosimilar drugs from the company’s portfolio are currently marketed in the United States. Please note that Biogen had a joint venture with Samsung Bioepis for the development and commercialization of its biosimilar drugs. However, Biogen announced an agreement last month to sell its 49.9% equity stake in the joint venture for up to $2.3 billion. Per the terms of the agreement, the companies will continue with their exclusive agreements for the commercialization of Flixabi, Benepali and Imraldi. Biogen will also keep commercial rights for Byooviz and SB15.
Biogen Inc. Price
Biogen Inc. price | Biogen Inc. Quote
Zacks Rank & Stock to Consider
Biogen currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Vir Biotechnology (VIR), which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vir Biotechnology’s earnings per share estimates for 2022 have increased from $4.77 to $6.53 in the past 30 days.
Earnings of Vir Biotechnology beat estimates twice in the last four quarters, delivering a surprise of 12.95%, on average.